See more : Traeger, Inc. (COOK) Income Statement Analysis – Financial Results
Complete financial analysis of Aditxt, Inc. (ADTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aditxt, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Continental Aktiengesellschaft (CON.DE) Income Statement Analysis – Financial Results
- North Peak Resources Ltd. (NPR.V) Income Statement Analysis – Financial Results
- Reunert Limited (RLO.JO) Income Statement Analysis – Financial Results
- Inform P. Lykos Holdings S.A. (LYK.AT) Income Statement Analysis – Financial Results
- Wuhan DR Laser Technology Corp.,Ltd (300776.SZ) Income Statement Analysis – Financial Results
Aditxt, Inc. (ADTX)
About Aditxt, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 645.18K | 933.72K | 105.03K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.84K | 766.78K | 77.98K | 17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -111.66K | 166.94K | 27.06K | -17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -17.31% | 17.88% | 25.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.07M | 7.27M | 5.04M | 937.97K | 175.44K | 525.00K | 0.00 |
| General & Administrative | 18.61M | 15.99M | 22.08M | 7.85M | 5.69M | 5.04M | 851.94K |
| Selling & Marketing | 269.28K | 1.85M | 334.98K | 81.99K | 551.00 | 39.84K | -638.96K |
| SG&A | 18.88M | 17.84M | 22.42M | 7.93M | 5.70M | 5.08M | 212.99K |
| Other Expenses | 0.00 | 58.96K | 14.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.95M | 25.10M | 27.46M | 8.87M | 5.87M | 5.61M | 212.99K |
| Cost & Expenses | 26.71M | 25.87M | 27.54M | 8.87M | 5.87M | 5.61M | 212.99K |
| Interest Income | 10.17K | 57.35K | 3.10K | 563.00 | 1.93K | 0.00 | 0.00 |
| Interest Expense | 6.39M | 2.29M | 1.94M | 310.08K | 1.93K | 79.77K | 0.00 |
| Depreciation & Amortization | 542.58K | 535.98K | 476.24K | 17.77K | 5.87M | 5.61M | 851.94K |
| EBITDA | -25.46M | -24.83M | -43.96M | -8.85M | 45.00K | 0.00 | 638.96K |
| EBITDA Ratio | -3,945.89% | -2,600.78% | -25,663.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26.06M | -24.94M | -27.43M | -8.87M | -5.87M | -5.61M | -212.99K |
| Operating Income Ratio | -4,039.58% | -2,670.64% | -26,120.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.33M | -2.17M | -4.44M | -277.02K | 43.07K | -79.77K | 0.00 |
| Income Before Tax | -32.39M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -212.99K |
| Income Before Tax Ratio | -5,020.40% | -2,961.28% | -44,148.91% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 543.94K | 1.94M | 310.08K | 1.93K | -161.14K | -851.94K |
| Net Income | -32.38M | -28.19M | -48.31M | -9.46M | -5.83M | -5.69M | -212.99K |
| Net Income Ratio | -5,018.92% | -3,019.53% | -45,994.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| EPS Diluted | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| Weighted Avg Shares Out | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
| Weighted Avg Shares Out (Dil) | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF)...
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, October 11, 2024, at 11:30 AM...
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024 year-end. Business and Acquisitions Aditxt's two acquisition targets, Evofem Biosciences, Inc....
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading...
Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, Inc. (“Pearsanta”), has entered into a Market Development Collaboration Agreement...
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright...
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on...
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these...
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO...
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a securities purchase agreement with...
Source: https://incomestatements.info
Category: Stock Reports